miR-342-5p and AnkG pathway in early Alzheimer's synapse changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will compare people with probable Alzheimer's dementia to healthy age-matched controls to study changes in the miR-342-5p/AnkG pathway linked to early synaptic dysfunction. Participants will undergo cognitive screening, brain MRI confirmation, blood collection, and optional cerebrospinal fluid collection with consent. The team will measure pathway components in peripheral blood and CSF and correlate those levels with cognitive scores and MRI findings. The goal is to clarify mechanisms of early synaptic abnormality and identify accessible biomarkers for earlier diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Inclusion criteria for AD group:

1. Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
2. MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score \<4 points
3. Brain MRI showing bilateral temporal lobe and hippocampal atrophy
4. Age ≥50 years

Inclusion criteria for control group:

1. Healthy subjects with age matched to the AD group
2. Normal cognitive function and good activities of daily living
3. No dementia patients among first-degree relatives
4. Negative brain MRI and neurological examination

Exclusion Criteria:

1. Dementia or cognitive impairment caused by other diseases
2. History of substance abuse
3. Progressive primary aphasia
4. Previous traumatic brain injury
5. Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems
6. Impaired consciousness and inability to cooperate
7. Other conditions unsuitable for inclusion

Where it's running

• The Fourth Affiliated Hospital of Zhejiang University School of Medicine
  Yiwu, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xu-hua Xu
• Email: fupinglangying@zju.edu.cn
• Phone: +8613705790560

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

• Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease

  This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.

  Recruiting Anhui Medical University · Hefei, Anhui · NCT07827196

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.